ArticleThe American journal of tropical medicine and hygiene2025
The Value of Fecal Calprotectin Combined with Procalcitonin in the Differential Diagnosis of Bacterial and Viral Diarrhea in Children.
Article in The American journal of tropical medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gut microbiome dynamics in acute infectious diarrhea: A conceptual framework from acute dysbiosis toward precision restoration (Review).Experimental and therapeutic medicine · 2026Review
- Performance of fecal calprotectin and serum procalcitonin for the diagnosis of spontaneous bacterial peritonitis in patients with cirrhosis: A prospective diagnostic accuracy study.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026Article
- Current status and future perspectives of fecal immunological markers in the differential diagnosis of Clostridioides difficile infection in children.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infectious diarrhea frequently occurs in children, and accurate diagnosis is essential for providing prompt treatment. Fecal calprotectin (FC) and procalcitonin (PCT) are useful in differentiating types of infectious diarrhea. Therefore, this study aims to assess the value of combining FC and PCT in the differential diagnosis of bacterial and viral diarrhea in children. As a retrospective study, convenience sampling was used to include 60 children with acute bacterial diarrhea (bacterial group) and 70 children with acute viral diarrhea (viral group) who were admitted to hospitals in China between October 2019 and October 2021. The demographic characteristics, medical history, and laboratory data of the children were collected and compared. The proportions of children with myocardial and liver damage were lower in the bacterial group than in the viral group, and the proportions of children with bloody stool and purulent stool were higher in the bacterial group than in the viral group (all P <0.001). The levels of FC, PCT, C-reactive protein (CRP), and white blood cells (WBCs) were elevated in patients in the bacterial group compared with those in the viral group (all P <0.05). The FC, PCT, CRP, and WBC count values are valuable in the differential diagnosis of bacterial and viral diarrhea, and the area under the curve of FC combined with PCT for the differential diagnosis was the largest at 0.933, with a 95% CI of 0.856-0.955. Fecal calprotectin is superior to PCT, CRP, and WBC count in terms of guiding the differential diagnosis. The combination of FC and PCT provides better guidance for differential diagnosis than each indicator used individually.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.